Latest Investments News

Alice Queen Limited has raised $1 million through convertible notes to fund ongoing gold and copper exploration and support working capital needs.

Peak Rare Earths shareholders have overwhelmingly approved Shenghe Resources’ acquisition scheme, setting the stage for imminent court approval and a cash payout.

Fat Prophets Global Contrarian Fund has successfully closed its Share Purchase Plan, raising nearly $1 million from existing shareholders. The capital injection will see over 740,000 new shares issued at a modest discount.

Mad Paws Holdings has secured Foreign Investment Review Board approval for Rover Group’s full acquisition scheme, with the board unanimously recommending shareholder support.

Cobalt Blue Holdings has secured a crucial works approval for its Kwinana Cobalt Refinery, pushing Australia’s first dedicated cobalt processing plant closer to a final investment decision by the end of 2025.

Tivan Limited has raised $15 million through a strategic share placement led by ETFS Capital, positioning the company for key project acquisitions and development in fluorite and tungsten mining.

333D Limited has confirmed a $1 million placement to fund significant upgrades to its digital asset management platform, explaining a recent sharp rise in its share price and trading volume.

Falcon Metals has reported impressive high-grade gold intercepts at its Blue Moon prospect, confirming continuation of historic reef lines and securing a second drill rig to accelerate exploration.

Assetora Limited has locked in a $3 million private placement from CloudTech Group, aiming to strengthen its balance sheet and fuel expansion plans. The deal unfolds in two tranches, with key conditions tied to audited reports and ASX reinstatement.

Global Uranium and Enrichment Limited reports promising uranium intercepts from ongoing drilling at its Pine Ridge Project, reinforcing its development potential in the Powder River Basin.

Brightstar Resources reports underground mining operations at its Laverton Hub are significantly ahead of schedule, targeting a +50% quarter-on-quarter production increase in the September quarter. The Fish Mine has turned cash flow positive, underpinning a robust growth outlook.

Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.